This post was originally published on this site A new web-based tool, called PREDICT Prostate, incorporates patients’ clinical and demographic data to provide a personalized prognosis to men with prostate cancer, helping them choose between radical treatment or watchful waiting. The online tool was launched the same day the results of the study, “Individual prognosis…
Conditions
Conditions
Phase 1 Trial of CA-4948 Recruiting Non-Hodgkin’s Lymphoma Patients
This post was originally published on this site A Phase 1 clinical trial is recruiting relapsed or refractory non-Hodgkin’s lymphoma patients to determine the safest and most effective dose of the oral therapy CA-4948. The trial is now treating patients in its fifth dosing group, Curis announced. CA-4948, developed by Curis in collaboration with Aurigene, is a small molecule that works by…
ADXS-PSA/Keytruda Combo Prolongs Survival in mCRPC, Early Trial Results Suggest
This post was originally published on this site Adding ADXS-PSA, an investigational cancer vaccine, to Keytruda (pembrolizumab) is showing positive signs of safety and efficacy in patients with metastatic, castration-resistant prostate cancer (mCRPC), and appears to prolong survival compared with standard-of-care therapy, early results from an ongoing Phase 1/2 trial show. The results were announced…
New Research Unit at England’s University of East Anglia to Study Possible Link Between Sleep and Dementia
This post was originally published on this site To enable researchers to study prospective links between sleep and dementia, a cutting-edge sleep unit has opened at the University of East Anglia (UEA) in Norwich, England. While sleeping issues commonly occur in dementia, it’s unclear whether diseases such as Alzheimer’s cause the disturbances, or whether problems sleeping…
Tips to Help Patients and Loved Ones Face an Alzheimer’s Diagnosis
This post was originally published on this site The Alzheimer’s Association estimates that nearly 5.8 million people in the United States have the condition. Most people who are diagnosed with Alzheimer’s disease are 65 or older, but the disease is found across all age groups, including 200,000 with an early-onset diagnosis. The adage that “there’s…
Surgery Extends Lives of Women with Metastatic Breast Cancer, Study Says
This post was originally published on this site Women with HER2-positive breast cancer that has spread to distant organs live longer if they have surgery to remove their primary tumor, according to research presented at the recent American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. The findings were featured on the…
Early Phase 3 Trial Results of Tedopi for Advanced NSCLC Are Positive
This post was originally published on this site Early results from the ATALANTE-1 Phase 3 trial indicate that Tedopi benefits people with advanced non-small cell lung cancer (NSCLC) who failed to respond to prior checkpoint inhibitor therapy, OSE Immunotherapeutics reported. Three enrolled patients responded positively to third-line treatment with Tedopi, either achieving a partial reduction…
Living In-between
This post was originally published on this site I have been a follicular lymphoma patient since 2008. One of the strangest things about this disease is the kind of “in-between-ness” that it can put some patients into. You’re not really cured, but you’re not really sick, either. (Terrilyn McCormick writes about this very well.) You…
Age, Obesity, Comorbidities Linked with Severe Fatigue Among Non-Hodgkin’s Lymphoma Survivors
This post was originally published on this site While a significant proportion of non-Hodgkin’s lymphoma survivors suffer from severe fatigue, the type of initial treatment and Rituxan (rituxumab) use did not influence this outcome, a new study shows. Instead, severe fatigue was found to be correlated with increased age, obesity, and the presence of other comorbidities.…
Janssen Seeks Approval of Darzalex Add-on for Newly Diagnosed Multiple Myeloma Patients in Japan
This post was originally published on this site Janssen has submitted an application to Japanese authorities seeking the approval of Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and dexamethasone — for the treatment of newly diagnosed multiple myeloma patients ineligible for high-dose chemotherapy and stem cell transplant. The supplemental new drug application, which will be considered under priority review, is based on data from…
Long-term Use of Oral Contraceptives Protects Against Deadliest Forms of Ovarian Cancer, Large Study Finds
This post was originally published on this site Long-term use of oral contraceptives protects women from the most lethal types of ovarian cancers, a large multi-center study has found. The study, “Oral contraceptive use and risk of highly fatal ovarian cancer: Evidence from the Ovarian Cancer Association Consortium,” was recently presented at the 2019 American…
MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients
This post was originally published on this site The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed’s investigational CAR T-cell product, CD44v6, for the treatment of acute myeloid leukemia and multiple myeloma, the company announced. The Phase 1/2 trial will be conducted at two clinical centers in Italy — the San Raffaele Hospital in…